Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Preclinical analysis shows significant antitumor activity in TNBC, highlighting toxicity challenges with TROP2 targeting.

TROP2 CAR-T cells exhibit strong antitumor activity against triple-negative breast cancer cell lines.
In vivo testing with xenograft models reveals severe off-tumor toxicity in TROP2-humanized mice.
An AND-logic gated SynNotch CAR targeting B7-H3 demonstrates comparable antitumor efficacy with reduced toxicity.
These findings indicate the need for cautious application of TROP2 targeting in clinical settings due to potential organ damage.

Sun et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark